Pro-gastrin-releasing peptide (ProGRP) as a biomarker in small-cell lung cancer diagnosis, monitoring and evaluation of treatment response
Ewa Wojcik, Jan Kanty Kulpa Department of Clinical Biochemistry, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Cracow, Poland Abstract: Lung cancer belongs to malignant tumors that possess the highest rates of morbidity and mortality in the world. A number of morp...
Guardado en:
Autores principales: | Wojcik E, Kulpa JK |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ea2d2ea8ebc541d28130334646b8eb47 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Biomarkers for Treatment Response in Advanced Prostate Cancer
por: Samia Asif, et al.
Publicado: (2021) -
Molecular Markers to Predict Prognosis and Treatment Response in Uterine Cervical Cancer
por: Maximilian Fleischmann, et al.
Publicado: (2021) -
hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Karen Aughton, et al.
Publicado: (2021) -
Gastrin-17 Combined with CEA, CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer
por: Wang Z, et al.
Publicado: (2021) -
Biomarkers in cancer
Publicado: (2009)